- Home
- SLNO vs IMNM Comparison
SLNO vs IMNM Comparison
Compare SLNO & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLNO | IMNM |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | United States | United States |
| Employees | N/A | 168 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.8B |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SLNO | IMNM |
|---|---|---|
| Price | $39.79 | $23.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | ★ $112.70 | $31.22 |
| AVG Volume (30 Days) | 1.5M | ★ 1.8M |
| Earning Date | 02-26-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $98,675,000.00 | $9,679,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $159.08 | $11.53 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $37.95 | $5.15 |
| 52 Week High | $90.32 | $27.65 |
Technical Indicators
Market Signals| Indicator | SLNO | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 40.84 | 48.17 |
| Support Level | $39.23 | $24.03 |
| Resistance Level | $41.84 | $27.65 |
| Average True Range (ATR) | 2.02 | 1.54 |
| MACD | 0.06 | -0.32 |
| Stochastic Oscillator | 21.76 | 13.27 |
Price Performance
Historical ComparisonAbout SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.